Suven Life Sciences Announces First Subjects Dosed in Phase-1 Clinical Trial of SUVN-16107, a True Muscarinic M1 Positive Allosteric Modulator for Cognitive Disorders Treatment

Suven Life Sciences, a clinical stage biopharmaceutical company, has announced that the first subjects have been dosed in a Phase-1 clinical trial of SUVN-16107 in the USA under FDA acceptance of Investigational New Drug (IND) and issue of Study May Proceed letter. SUVN-16107 is the fifth internally discovered compound to advance into clinical trials and an exciting addition to Suven’s extensive, fully-owned pipeline of oral small molecules aimed at addressing large disease populations with significant unmet need in neuroscience. The Phase-1 trial is a two-part randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-16107 in healthy subjects. SUVN-16107 is a novel, potent, and selective muscarinic M1 positive allosteric modulator with minimal agonist-like activity, designed for CNS disorders such as Alzheimer’s disease, sleep disorders, major depressive disorders, Parkinson’s disease, Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven Life Sciences owns the intellectual property rights for SUVN-16107 in all major markets.